Irisin and Cardiometabolic Disorders in Obesity: a Systematic Review
Source : https://www.hindawi.com/journals/iji/2023/5810157/
Overweight and obesity are global health issues, impacting a significant portion of young adults. Obesity is a complex condition influenced by genetics and environmental factors, leading to increased susceptibility to...
The review suggests that irisin plays a significant role as both a preventive measure and a biomarker for comorbidities linked to obesity and cardiometabolic disorders.
Share
Effect of Combined Administration of Acyl-CoA: Cholesterol Acyltransferase 1 Inhibitor and Glucagon-Like Peptide 1 Receptor Agonist on a Rodent Model of Diet-Induced Obesity
Source : https://www.sciencedirect.com/science/article/abs/pii/S0006291X23012585?via=ihub
A glucagon-like peptide 1 receptor agonist (GLP-1 RA) semaglutide was approved for the treatment of obesity by the Food and Drug Administration. Howev...
Collectively, these findings suggest combining semaglutide and avasimibe could be an effective approach to weight management.
Share
Impact of a Pharmacist-Led Weight Management Service in a Cardiology Clinic
Source : https://pubmed.ncbi.nlm.nih.gov/37944862/
Pharmacist-led management of GLP-1 RA in patients with obesity or overweight led to clinically significant weight loss and improvements in weight-related comorbidities.
Pharmacist-led management of GLP-1 RA in patients with obesity or overweight led to clinically significant weight loss and improvements in weight-related comorbidities.
Share
Are We Ready to Recommend Capsaicin for Disorders Other Than Neuropathic Pain?
Source : https://www.mdpi.com/2072-6643/15/20/4469
Capsaicin, a lipophilic, volatile compound, is responsible for the pungent properties of chili peppers. In recent years, a significant increase in investigations into its properties has allowed the production of...
Type 2 diabetes and dyslipidemia are closely linked to obesity and, consequently, could be beneficiated by capsaicin supplementation.
Share
Effect of Long-Acting Versus Short-Acting Glucagon-Like Peptide-1 Receptor Agonists on Improving Body Weight and Related Metabolic Parameters in Type 2 Diabetes: a Head-to-Head Meta-Analysis
Source : https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10615555/
Glucagon-like peptide-1 receptor agonists (GLP-1RAs) showed great value in treating nonalcoholic fatty liver disease (NAFLD).
Long-acting GLP-1RAs may be more promise than short-acting GLP-1RAs in improving weight and related metabolic parameters.
Share